QuantuMDx’s investment to mass manufacture diagnostic device, disposable test cassette

 KUALA LUMPUR, Dec 17 -- QuantuMDx Group Limited, a UK-based life sciences company is investing over £11 million to scale up production to mass manufacture its flagship diagnostic device, Q-POC™ and disposable test cassette. (£1 = RM 5.469)

QuantuMDx accelerated development, scale-up and manufacture of Q-POC™ - its rapid point-of-care testing system - earlier this year in response to the COVID-19 pandemic.

Q-POC™ is a portable, PCR device offering rapid, sample-to-answer, molecular diagnostic testing at the point of care, with results in approximately 30 minutes.

The Q-POC™ system comprises a sample collection kit, single-use test cassette and analyser, according to a statement.

The company’s first commercial assay for Q-POC™ will detect SARS-CoV-2, the virus causing COVID-19, and Flu A & B, providing a powerful rapid PCR diagnostics and surveillance tool for clinicians and public health officials.

Rapid scale-up manufacturing of QuantuMDx’s SARS CoV-2 Flu A/B disposable test cassettes is currently taking place.

QuantuMDx has worked with development partner, RD Support from concept, through design and optimisation, to pilot manufacture in Denmark and design transfer to Singapore-based high volume manufacturer, Univac.

QuantuMDx expects to achieve CE-IVD marking for its Q-POC™ system in early 2021, following a release for research use only.

More details at www.quantumdx.com.

-- BERNAMA